The Role Of Community Pharmacy in Post Hospital Management of Patients Initiated on Warfari
Not Applicable
- Conditions
- Medication misadventure reduction in patients discharged from hospital after being commenced on warfarin or whose warfarin treatment was disrupted due to hospitalisation.Blood - Haematological diseases
- Registration Number
- ACTRN12608000334303
- Lead Sponsor
- The Unit for Medication Outcomes Research and Education, University of Tasmania
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
Minimum age :18years
Maximum age: no limit
Gender: both males and females
Health: must have had their warfarin treatment disrupted due to hospitalisation or have been initiated on warfarin.
Exclusion Criteria
Language; Non English speaking
Other studies: Participation in a concurrent other study.
Demographics; not-home based on discharge or no GP
Dementia.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The development of a model supporting the role of the pharmacy profession in improving the transition between hospital and community-based care for patients taking warfarin. The evaluation which will be used to inform the development of this model will include process indicators and clinical outcomes from the study such as INR control and bleeding events in addition to participant satisfaction, determined by a questionnaire and the reconciliation of qualitative interviews and focus group sessions with key stakeholders.[90 days after discharge]
- Secondary Outcome Measures
Name Time Method To demonstrate that the proposed Patient Self Monitoring (PSM) model is feasible and that patients, their general practitioners and pharmacists are satisfied with this model of care. Clinical outcomes, such as the time of the INR in therapeutic range (TTR), and participant and stakeholder feedback (GP's and community pharmacists) via questionnaires will inform this part of the study. Issues raised will allow the refinement of the PSM phase of this trial.[180 days after discharge]